Intarcia Appeals Advisory Committee On Diabetes Drug-Device Combo, Claiming ‘Misrepresentation’

 
• By Brenda Sandburg
Appeal filing
Intarcia appeals the decision of FDA advisory committee that benefits of its diabetes treatment do not outweigh its risks. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers